Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that can restore and preserve vision for patients with serious posterior eye diseases. Clearside's proprietary SCS Microinjector™, targeting the suprachoroidal space (SCS), provides unique access to the macula, retina, and choroid, where vision-threatening diseases often occur. The company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure designed to deliver targeted administration to the site of disease and is intended for use with established and novel drug formulations as well as future therapeutic innovations, such as gene therapy.